Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives.

[1]  G. Parker,et al.  Pharmacodynamic assessment of the anti-angiogenic and anti-vascular properties of bevacizumab by magnetic resonance imaging in metastatic colorectal carcinoma (CRC) , 2008 .

[2]  K. Flaherty,et al.  Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.

[3]  David J Collins,et al.  Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy , 2008, Nature Clinical Practice Oncology.

[4]  Y. Tomizawa,et al.  Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. , 2008, Lung cancer.

[5]  D. Buckley.  Are measurements from two commercial software packages interchangeable? Possibly, if like is compared with like. , 2008, Radiology.

[6]  A. D. Van den Abbeele,et al.  CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. , 2007, AJR. American journal of roentgenology.

[7]  K. Davies,et al.  Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2 , 2007, Clinical Cancer Research.

[8]  J. Griffiths,et al.  Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging. , 2007, International journal of radiation oncology, biology, physics.

[9]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Caleb Roberts,et al.  Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma , 2007, Clinical Cancer Research.

[11]  Michael L Maitland,et al.  Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[12]  W. Oyen,et al.  Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer , 2007, Journal of Nuclear Medicine.

[13]  J. Drevs,et al.  Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Earl,et al.  RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate. Cambridge GIST study group experience , 2007 .

[15]  M. Koukourakis,et al.  Early Antivascular Effects of Bevacizumab Anti-VEGF Monoclonal Antibody on Colorectal Carcinomas Assessed With Functional CT Imaging , 2007, American journal of clinical oncology.

[16]  Haesun Choi,et al.  We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Robert A. Beckman,et al.  Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[19]  Peter D. Esser,et al.  Quantitative contrast-enhanced computed tomography: is there a need for system calibration? , 2007, European Radiology.

[20]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[22]  Sanjiv S. Gambhir,et al.  How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.

[23]  Michael E. Phelps,et al.  Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase Inhibitors , 2006, Clinical Cancer Research.

[24]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[25]  A. Jubb,et al.  Predicting benefit from anti-angiogenic agents in malignancy , 2006, Nature Reviews Cancer.

[26]  E. Van Cutsem,et al.  Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Shim,et al.  [18F]fluorothymidine (FLT) PET after 3 days of gefitinib treatment and tumor response in non-small cell lung cancer (NSCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Adriaan A. Lammertsma,et al.  How should we analyse FDG PET studies for monitoring tumour response? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  Paul Workman,et al.  Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.

[32]  S. Larson,et al.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  Antoni B. Chan,et al.  On measuring the change in size of pulmonary nodules , 2006, IEEE Transactions on Medical Imaging.

[34]  C. Charnsangavej,et al.  Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[35]  Kevin Camphausen,et al.  Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Larson,et al.  The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development , 2005, Clinical Cancer Research.

[37]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  Eric Masson,et al.  Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Esserman,et al.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. , 2005, AJR. American journal of roentgenology.

[40]  D. Alsop,et al.  Arterial spin labeling MRI detects early recurrence and anti-angiogenic drug effect in recurrent malignant gliomas , 2005 .

[41]  J. Hainsworth,et al.  A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) , 2005 .

[42]  B. Condon,et al.  Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? , 2005, AJNR. American journal of neuroradiology.

[43]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[44]  David C. Alsop,et al.  Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma1 , 2005 .

[45]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[46]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[47]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Provenzale,et al.  A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[50]  F. Kabbinavar,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Simina C. Fluture,et al.  Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. , 2004, Radiology.

[52]  Mithat Gonen,et al.  Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[54]  J. Yap,et al.  Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J R Griffiths,et al.  Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging , 2003, British Journal of Cancer.

[57]  Felicia Zito,et al.  PET instrumentation and reconstruction algorithms in whole-body applications. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  Jamal Zweit,et al.  Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.

[59]  P. Price,et al.  Clinical measurement of blood flow in tumours using positron emission tomography: a review. , 2002, Nuclear medicine communications.

[60]  A. Padhani,et al.  The RECIST criteria: implications for diagnostic radiologists , 2001 .

[61]  Yasuhiro Inoue,et al.  Localization and trafficking of membrane-bound MMPs , 2001 .

[62]  K. Miles,et al.  Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules. , 2001, Radiology.

[63]  J. Baselga,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, New England Journal of Medicine.

[64]  A P Pathak,et al.  Utility of simultaneously acquired gradient‐echo and spin‐echo cerebral blood volume and morphology maps in brain tumor patients , 2000, Magnetic resonance in medicine.

[65]  J. Gibbs.  Mechanism-based target identification and drug discovery in cancer research. , 2000, Science.

[66]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[67]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[68]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[69]  Ting-Yim Lee,et al.  An Adiabatic Approximation to the Tissue Homogeneity Model for Water Exchange in the Brain: I. Theoretical Derivation , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[70]  A A Lammertsma,et al.  Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. , 1992, Cancer research.

[71]  N. Alpert,et al.  Strategy for the Measurement of Regional Cerebral Blood Flow Using Short-Lived Tracers and Emission Tomography , 1984, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[73]  T. Wilson,et al.  A model for capillary exchange. , 1966, The American journal of physiology.

[74]  S. Kety.  The theory and applications of the exchange of inert gas at the lungs and tissues. , 1951, Pharmacological reviews.

[75]  Michael E Phelps,et al.  Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs , 2008, Nature Clinical Practice Oncology.

[76]  G. Giaccone,et al.  Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). , 2008, European journal of cancer.

[77]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[78]  Alan Jackson,et al.  Dynamic contrast-enhanced magnetic resonance imaging in oncology , 2005 .

[79]  Geoffrey J. M. Parker,et al.  Tracer Kinetic Modelling for T1-Weighted DCE-MRI , 2005 .

[80]  A. Jackson,et al.  Analysis of dynamic contrast enhanced MRI. , 2004, The British journal of radiology.

[81]  K. Miles,et al.  Perfusion CT for the assessment of tumour vascularity: which protocol? , 2003, The British journal of radiology.

[82]  T. A. Smith,et al.  Facilitative glucose transporter expression in human cancer tissue. , 1999, British journal of biomedical science.

[83]  P. Tofts.  Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[84]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[85]  X Golay,et al.  Non-invasive Measurement of Perfusion: a Critical Review of Arterial Spin Labelling Techniques , 2022 .